Obesity-drug specialists Arena Pharmaceuticals (ARNA) and VIVUS (VVUS) have already launched their products in the United States, but both have struggled to get the green light in the European Union. While the two fight for market share in the U.S., Orexigen Therapeutics (NASDAQ: OREX), the third major player in this space, announced last week that it has submitted an application with the European Medicines Agency for the approval of its obesity medication Contrave. Orexigen has yet to get its drug approved by the FDA, but could it beat both Arena and VIVUS to the European market? Analysts David Williamson and Max Macaluso discuss this story in the following video.
Arena and VIVUS have been failed to get their drugs on the market in the EU, but can Orexigen jump over the regulatory hurdle and beat them to market?
David Williamson owns shares of Facebook. Max Macaluso, Ph.D. owns shares of Apple. The Motley Fool recommends and owns shares of Amazon.com, Apple, Facebook, and Google. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.